WSTAM
REGN icon

Wilbanks Smith & Thomas Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-72
Closed -$29K – 1084
2018
Q3 		$29K Buy
+72
New +$27.4K ﹤0.01% 800

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's REGN Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 72 shares — an estimated $29K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in REGN in Q3 2018 and held it in 1 quarter. The position peaked at $29K in Q3 2018. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 72 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $29K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Regeneron Pharmaceuticals position peaked at $29K in Q3 2018.
  • 670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.